Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689889 | 0.91 | ALDH1A1 (0.34) | ALDH1A1POLBKMT2ALOXMAPT | |
| SCHEMBL3684588 | 0.90 | HTT (0.33) | ALDH1A1KMT2AMAPTLMNA | |
| Trifluoroacetic Acid SCHEMBL3679528 | 0.86 | AKR1C3 (0.35) | ALDH1A1POLBKMT2AAKR1C3NR3C1 | |
| Trifluoroacetic Acid SCHEMBL3679525 | 0.86 | AKR1C3 (0.35) | ALDH1A1POLBKMT2AAKR1C3NR3C1 | |
| SCHEMBL13409991 | 0.85 | AKR1C3 (0.39) | ALDH1A1POLBKMT2AAKR1C3NR3C1 | |
| SCHEMBL3682807 | 0.84 | MMP2 (0.36) | — | |
| SCHEMBL3677505 | 0.81 | MMP9 (0.40) | — | |
| Trifluoroacetic Acid SCHEMBL3689890 | 0.77 | EEF2K (0.35) | ALDH1A1LOXMAPTLMNA | |
| Trifluoroacetic Acid SCHEMBL3689887 | 0.77 | EEF2K (0.35) | ALDH1A1LOXMAPTLMNA | |
| SCHEMBL3683027 | 0.76 | MMP9 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | ALDH1A1 236/4885POLB 1534/4885KMT2A 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.